Loading organizations...
Carlsbad, California-based Cytonus Therapeutics is a biotechnology company that develops engineered adoptive cellular therapy platforms for the targeted delivery of immunotherapeutics, biological payloads, and vaccines. The enterprise utilizes its proprietary Cargocyte technology to safely transport these therapeutic payloads directly to hard-to-reach tissues, addressing severe medical conditions such as pancreatic adenocarcinoma, infectious diseases, and cognitive disorders. In December 2018, the private biotech firm raised $70,000 in debt securities toward a planned $3 million venture funding round to support the advancement of its lead oncology program, GM1215. The organization operates with direct scientific ties to the University of California, San Diego, and recently expanded its corporate leadership by appointing Christopher Thorne as Chairman ahead of presenting at the BIO CEO & Investor Conference. Cytonus Therapeutics was officially founded in 2018 by medical doctor Remo Moomiaie-Qajar and university professor Richard Klemke.
Cytonus Therapeutics has raised $11.7M across 1 funding round.
Cytonus Therapeutics has raised $11.7M in total across 1 funding round.
Cytonus Therapeutics has raised $11.7M across 1 funding round. Most recently, it raised $11.7M Series A in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 4, 2023 | $11.7M Series A | JAE AN | John Ballantyne, Creative Ventures, Gemseki, Kreamedica, Proxima Ventures, WS Investments | Announced |
Cytonus Therapeutics has raised $11.7M in total across 1 funding round.
Cytonus Therapeutics's investors include Jae An, John Ballantyne, Creative Ventures, Gemseki, KreaMedica, Proxima Ventures, WS Investments.
